ABSTRACT
INTRODUCTION
Effective screening for pre-eclampsia (PE) is provided by the application of Bayes' theorem to combine the a-priori risk from maternal characteristics and medical history with the results of various combinations of biophysical and biochemical measurements at different times during pregnancy [1] [2] [3] [4] [5] . Useful biomarkers at 11-13 and 19-24 weeks are uterine artery pulsatility index (UtA-PI), mean arterial pressure (MAP) and serum placental growth factor (PlGF), but not soluble fms-like tyrosine kinase-1 (sFlt-1) 2, 3 . At 30-34 and 35-37 weeks, UtA-PI, MAP, PlGF and sFlt-1 are useful biomarkers 4, 5 . Routine screening for PE by maternal serum sFlt-1 at 30-34 weeks' gestation can identify most pregnancies that will develop preterm PE and many of those that will develop term PE 6 . We have shown recently that, although serum sFlt-1 at 19-24 weeks is not a useful marker for PE developing after 32 weeks, the performance of screening for PE by serum sFlt-1 at 30-34 weeks was improved by inclusion of measurements in the second trimester 6 . In both unaffected pregnancies and those that develop PE, there is a high correlation between second-and early third-trimester measurements of serum sFlt-1. These results provide evidence in favor of the concept that certain combinations of highly correlated markers, some of which individually have poor discriminatory power, can improve the overall performance of screening 7, 8 . The objective of this study was to investigate whether the performance of screening for PE by the measurement of UtA-PI, MAP and PlGF at 30-34 weeks is improved by taking into account the measurements obtained in the first and second trimesters.
METHODS

Study design and participants
Data for this study were derived from prospective screening for adverse obstetric outcomes in women attending their routine second-and third-trimester hospital visits at King's College Hospital and Medway Maritime Hospital, UK. These visits, which were held at 11 + 0 to 13 + 6, 19 + 0 to 24 + 6 and 30 + 0 to 34 + 6 weeks' gestation, included recording of maternal characteristics and medical history 1 , ultrasound assessment of fetal growth, anatomy and wellbeing and measurement of UtA-PI, MAP and PlGF. Gestational age was determined from measurement of fetal crown-rump length at 11-13 weeks or fetal head circumference at 19-24 weeks 9, 10 . The women were screened between December 2010 and August 2014 and gave written informed consent to participate in the study, which was approved by the National Health Service Research Ethics Committee.
First-and third-trimester Doppler studies were carried out transabdominally; however a transvaginal approach was used in the second trimester because cervical length was also measured. At 11-13 weeks, a sagittal section of the uterus was obtained, the cervical canal and internal cervical os were identified, the transducer was tilted gently from side to side and color flow mapping was used to identify each uterine artery along the side of the cervix and uterus at the level of the internal os 11, 12 . At 19-24 weeks, women were asked to empty their bladder and were positioned in the dorsal lithotomy position. The ultrasound probe was inserted into the vagina and advanced in turn into the left and right lateral fornix. The uterine arteries were identified using color Doppler at the level of the internal cervical os 13 . At 30-37 weeks, color Doppler was used to identify each uterine artery at the apparent crossover with the external iliac arteries 12 . After identification of each uterine artery, pulsed-wave Doppler was used with the sampling gate set at 2 mm to cover the whole vessel. Care was taken to ensure that the angle of insonation was < 30
• and the peak systolic velocity was > 60 cm/s to ensure that the uterine artery, rather than the arcuate artery, was examined. When three similar consecutive waveforms were obtained, the PI was measured and the mean PI of the left and right arteries was calculated. MAP was measured by validated automated devices (3BTO-A2, Microlife, Taipei, Taiwan). Women were in the sitting position with their arms supported at the level of the heart and a small (22 cm), normal (22-32 cm) or large (33-42 cm) adult cuff was used, depending on the mid-arm circumference. After resting for 5 min, two recordings of blood pressure were made in both arms simultaneously. We calculated the final MAP as the average of all four measurements 14 . Maternal serum PlGF was measured by automated biochemical analyzers (DELFIA Xpress system, PerkinElmer Life and Analytical Sciences, Waltham, USA or Cobas e411 system, Roche Diagnostics, Penzberg, Germany) within 10 min of blood sampling.
The inclusion criteria for this study were singleton pregnancy delivering a phenotypically normal liveborn or stillborn neonate at any stage after the visit at 30-34 weeks. Pregnancies with major fetal abnormalities were excluded. For the visit at 30-34 weeks, all women with measurement of UtA-PI, MAP and/or PlGF were selected. For visits at 11-13 and 19-24 weeks, all women with measurements of UtA-PI, MAP and/or PlGF at this visit who also attended a visit at 30-34 weeks were selected.
Outcome measures
Data on pregnancy outcome were collected from the hospital maternity records or the general medical practitioners of the women. The obstetric records of all women with pre-existing or pregnancy-associated hypertension were examined to determine if the condition was PE, as defined by the International Society for the Study of Hypertension in Pregnancy 15 . Outcome measures were PE requiring delivery at any stage after the third-trimester assessment. The unaffected group contained all pregnancies without PE or pregnancy-induced hypertension (PIH).
Statistical analysis
Performance of screening for each biomarker was assessed, first, by modeling, whereby values on UtA-PI, MAP and PlGF were simulated for our 123 406 singleton pregnancies with available data on maternal factors 1 and, second, by examining the empirical results in pregnancies with complete data for a given biomarker at 11-13, 19-24 and 30-34 weeks.
Competing-risks model
This model assumes that, if pregnancy was to continue indefinitely, all women would develop PE and whether they do so or not before a specified gestational age depends on competition between delivery before or after development of PE. For any woman with specific maternal factors and biomarker multiples of the normal median (MoM) values, the posterior distribution of the time to delivery with PE, assuming there is no other cause of delivery, is obtained from the application of Bayes' theorem. Gestational age at delivery with PE was defined by two components: first, the prior distribution based on maternal factors 1 and second, the conditional distribution of MoM biomarker values given the gestational age with PE and maternal factors. Values of UtA-PI, MAP, PlGF were expressed as MoMs adjusting for those characteristics found to provide a substantive contribution to their values, including the maternal factors, in the prior model [16] [17] [18] . Multivariable Gaussian distributions were fitted to the first-, second-and third-trimester log 10 MoM values of UtA-PI, MAP, PlGF and a common covariance matrix was assumed for these distributions. Analysis of residuals was used to check the adequacy of the model and assess the effects of maternal factors on log 10 MoM values in pregnancies with PE. 
Model-based estimates of screening performance
To provide model-based estimates of screening performance, the following procedure was adopted. First, we obtained the dataset of 123 406 singleton pregnancies that was used previously to develop a model for PE based on maternal demographic characteristics and medical history 1 . Second, for each case of PE (n = 2748) and pregnancies unaffected by PE or PIH (n = 117 710), MoM values for first-, second-and third-trimester UtA-PI, MAP and PlGF were simulated from the fitted multivariate Gaussian distribution for log-transformed MoM values. Third, risks were obtained using the competing-risks model from the simulated MoM values and pregnancy characteristics. These three steps were applied to the pregnancies within the unaffected group with no restriction on time of delivery. Fourth, for a given FPR, risks from the unaffected group were used to define a risk cut-off. The proportion of PE risks was then used to obtain an estimate of the associated detection rate. The area under the receiver-operating characteristics (ROC) curve (AUC) was also calculated. The simulations were repeated 100 times to reduce variability due to the simulation process and provide suitably precise model-based estimates of performance.
Empirical performance of screening
Ten-fold cross-validation was used to assess the empirical performance of screening for PE by maternal factors and the combination of maternal factors and each of the three biomarkers. The data were divided into 10 equal subgroups, the model was then fitted 10 times to different combinations of nine of the 10 subgroups and used to predict risk of PE in the remaining tenth of the data. In each case, the regression models and the covariance matrix were fitted to the training dataset comprising nine-tenths of the data and used to produce risks for the hold-out sample comprising the remaining tenth of the data. Our fitted model 1 for maternal factors was assumed for the prior distribution of time to delivery with PE, assuming no other cause of delivery.
Mahalanobis distances
The Mahalanobis distance provides a simple measure of the separation between the fitted distributions of log-transformed MoM values in unaffected pregnancies and those that developed PE. For a single marker, the Mahalanobis distance is the difference in means between the PE and unaffected groups divided by the SD. For two or more markers, it is a generalization of this that takes account of the correlations. We present Mahalanobis distances between the distribution of log-transformed MoM values in unaffected pregnancies and those requiring delivery with PE at 34.2 weeks, the median gestational age for pregnancies delivering preterm for PE.
The statistical software package R was used for data analyses 19 . The survival package 20 was used for fitting the maternal factors model and the package pROC 21 was used for the ROC curve analysis.
RESULTS
Characteristics and data on maternal factors of the total population of 123 406 pregnancies are given in Timepoints 1, 2 and 3 correspond to screening at 11-13, 19-24 and 30-34 weeks, respectively. *Data for soluble fms-like tyrosine kinase-1 (sFlt-1) were derived from the study by Wright et al. 6 . MAP, mean arterial pressure; PlGF, placental growth factor; UtA-PI, uterine artery pulsatility index. Table S1 and of pregnancies with complete data for a given biomarker at 11-13, 19-24 and 30-34 weeks are given in Table S2 . The distributions of log 10 MoM values of UtA-PI, MAP and PlGF in pregnancies that developed PE and the SD for log 10 MoM values of each biomarker at 11-13, 19-24 and 30-34 weeks have been reported previously [22] [23] [24] . Estimated correlations for log 10 MoM values of each biomarker at 11-13, 19-24 and 30-34 weeks, from the pooled data of the PE and unaffected groups, are given in Table S3 . Empirical and model-based performance of screening for PE developing after the third-trimester visit by maternal factors and combinations of maternal factors with each biomarker at 11-13, 19-24 and 30-34 weeks are shown in Table 1 . The empirical performance of screening was consistent with the model-based results. The performance of screening for preterm PE at 30-34 weeks by UtA-PI, MAP or PlGF was not improved by the addition of the respective biomarker values obtained at 11-13 and/or 19-24 weeks; in the case of term PE, there was a small improvement in performance of screening.
The relationship between MoM values of UtA-PI, MAP and PlGF at 19-24 weeks and 30-34 weeks in unaffected pregnancies and pregnancies that developed PE and delivered after the third-trimester assessment but < 37 weeks' gestation are shown in Figure 1 ; the values are compared to those of sFlt-1 that were reported in a previous study 6 . In the case of UtA-PI, MAP and PlGF, combined screening at both 19-24 and 30-34 weeks has no or only marginal benefit over screening at 30-34 weeks alone. In contrast, screening by sFlt-1 at 30-34 weeks is substantially improved by the addition of data from 19-24 weeks 6 . The Mahalanobis distances between unaffected pregnancies and those with PE for the biomarkers measured at 11-13, 19-24 or 30-34 weeks and their combinations are shown in Table 2 . For UtA-PI, there was slightly more separation between unaffected and PE pregnancies at 19-24 than at 30-34 weeks and there was little benefit from their combination. For both MAP and PlGF, there was substantially more separation at 30-34 weeks than at 11-13 or 19-24 weeks and there was little benefit of combining the measurements at 30-34 weeks with those taken at earlier gestational ages. As reported in previous studies, sFlt-1 had very little separation at 11-13 or 19-24 weeks, but, at 30-34 weeks, the separation was larger than that for any other marker; inclusion of the measurements at 19-24 weeks increased the separation substantially 6, 25 .
DISCUSSION
Principal findings of this study
The findings of this study demonstrate that, in routine screening for PE by UtA-PI, MAP and serum PlGF at 30-34 weeks' gestation, the detection rate of preterm PE and term PE, at a given false-positive rate (FPR), is not substantially improved by inclusion of measurements from the first or second trimester. This is in contrast to the finding that the performance of screening by sFlt-1 at 30-34 weeks is improved by inclusion of measurements from the second trimester 6 . The prevailing view in multimarker screening tests for pregnancy complications is that, first, the individual markers should have good discriminatory power and second, there should be low correlations between markers so that they provide independent information. However, this view has been challenged by the demonstration that certain combinations of highly correlated markers, some of which individually have poor discriminatory power, can improve the overall performance of screening 7, 8 . For example, serum pregnancy-associated plasma protein-A (PAPP-A) in the second trimester is a very poor marker for trisomy 21, but the addition of second-trimester PAPP-A to first-trimester PAPP-A results in substantial improvement in the performance of screening by the latter 7, 8 . This is the consequence of a high correlation between first-and second-trimester levels of PAPP-A in both euploid and trisomic pregnancies. Thus, contrary to the intuition that highly correlated markers are unlikely to be useful, joint discrimination of this type is more likely to occur when the two marker values show high correlation.
In the case of sFlt-1, there is a relatively high correlation between second-and third-trimester levels and, although the latter provides good discrimination between PE and unaffected pregnancies, the former does not. The combination of two measurements separates the unaffected pregnancies from those with PE substantially more than either of the individual measurements, as illustrated in Figure 1 . This is also reflected in the increase in Mahalanobis distance achieved by including the second-trimester measurements with those in the third trimester. In the case of MAP and UtA-PI, there is a relatively low correlation between second-and third-trimester levels and the shift in pregnancies that develop PE is similar in the two trimesters. For PlGF, there is a relatively high correlation, but the shift in pregnancies with PE are such that the second-trimester measurements add little to those from the third trimester; this is shown in Figure 1 by the way in which the likelihood ratio contour is very similar to the 10 th percentile of the third-trimester measurement.
Strengths and limitations
The strengths of this study are, first, examination of a large population of pregnant women attending for routine care at three gestational-age ranges which are widely used for assessment of fetal anatomy and growth, second, recording of data on maternal characteristics and medical history to define the prior risk, third, expression of UtA-PI, MAP and PlGF values as MoMs after adjustment for factors that affect the measurements, fourth, use of Bayes' theorem to combine the prior risk with biomarkers to estimate the performance of screening for PE. A limitation of the study is that of optimistic bias in performance due to deriving and testing a model using the same dataset. We used 10-fold cross-validation to reduce such bias.
Clinical implications of the study
Extensive research in the last decade has led to the development of a two-stage strategy for identification of pregnancies at risk of PE 26 . The first stage involves risk stratification at 11-13 weeks with the aim of predicting preterm PE because the prevalence of this condition can be potentially reduced substantially by the prophylactic use of low-dose aspirin started before 16 weeks' gestation 27, 28 . The second-stage involves risk stratification in the second and third trimesters to predict both preterm PE and term PE, with the aim of improving outcome through close monitoring of high-risk pregnancies to define the best time, place and mode of delivery.
Risk stratification at 11-13 weeks by a combination of maternal factors, UtA-PI, MAP and PlGF can predict 75% of cases of preterm PE and about 45% of term PE at a FPR of 10% 2, 29 ; the respective values for risk stratification at 19-24 weeks are 85% and about 45% 3 . Risk stratification at 30-34 weeks by maternal factors, UtA-PI, MAP, PlGF and sFlt-1 detects 99% of preterm PE and 66% of term PE 4 . The findings of this study suggest that for screening at 30-34 weeks in women who had prior screening in the first and/or second trimester, there is no benefit in considering the results of UtA-PI, MAP or PlGF from such prior screening and only the results from testing at 30-34 weeks should be considered.
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